Literature DB >> 12396421

The role of particle properties in pharmaceutical powder inhalation formulations.

Nora Y K Chew1, Hak-Kim Chan.   

Abstract

Pharmaceutical aerosol delivery is undergoing dramatic changes in both inhaler device and formulation aspects. There is a rapid move from the traditional propellant-driven metered dose inhalers to the high performance liquid atomizers and dry powder inhalers (DPIs). DPIs involving the dispersion of powders into aerosols by an inhaler device are particularly attractive as dry powders generally have greater chemical stability than liquids used in atomizers. Delivery of therapeutic proteins as dry powder aerosols is of high commerical interest. However, production and formulation of dry powders for inhalation can be difficult and challenging due to the potential physical instability of the powder. Dry powders consisting of micro- or nano-sized particles are inherently adhesive and cohesive, leading to highly variable dose accuracy and poor aerosol performance. Particle engineering via the use of appropriate pharmaceutical excipients and processing parameters can produce particles of optimal morphologies and surface properties which would enhance aerosol generation. Some of the key determinants for successful dispersion of pharmaceutical powders suitable for inhalation are reviewed with an emphasis on the practical significance.

Mesh:

Substances:

Year:  2002        PMID: 12396421     DOI: 10.1089/089426802760292672

Source DB:  PubMed          Journal:  J Aerosol Med        ISSN: 0894-2684


  14 in total

1.  The role of capsule on the performance of a dry powder inhaler using computational and experimental analyses.

Authors:  Matthew S Coates; David F Fletcher; Hak-Kim Chan; Judy A Raper
Journal:  Pharm Res       Date:  2005-06-08       Impact factor: 4.200

Review 2.  Pharmaceutical particle engineering via spray drying.

Authors:  Reinhard Vehring
Journal:  Pharm Res       Date:  2007-11-28       Impact factor: 4.200

3.  Optimization of the fine particle fraction of a lyophilized lysozyme formulation for dry powder inhalation.

Authors:  Sarah Claus; Claudius Weiler; Joerg Schiewe; Wolfgang Friess
Journal:  Pharm Res       Date:  2013-04-09       Impact factor: 4.200

4.  Storage stability of inhalable phage powders containing lactose at ambient conditions.

Authors:  Rachel Yoon Kyung Chang; Martin Wallin; Elizabeth Kutter; Sandra Morales; Warwick Britton; Jian Li; Hak-Kim Chan
Journal:  Int J Pharm       Date:  2019-01-31       Impact factor: 5.875

Review 5.  Phage therapy for respiratory infections.

Authors:  Rachel Yoon Kyung Chang; Martin Wallin; Yu Lin; Sharon Sui Yee Leung; Hui Wang; Sandra Morales; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2018-08-07       Impact factor: 15.470

Review 6.  Physical stability of dry powder inhaler formulations.

Authors:  Nivedita Shetty; David Cipolla; Heejun Park; Qi Tony Zhou
Journal:  Expert Opin Drug Deliv       Date:  2019-12-13       Impact factor: 6.648

7.  Nanocomposite microparticles (nCmP) for the delivery of tacrolimus in the treatment of pulmonary arterial hypertension.

Authors:  Zimeng Wang; Julie L Cuddigan; Sweta K Gupta; Samantha A Meenach
Journal:  Int J Pharm       Date:  2016-08-26       Impact factor: 5.875

8.  Investigation of electrostatic behavior of a lactose carrier for dry powder inhalers.

Authors:  Keat Theng Chow; Kewu Zhu; Reginald B H Tan; Paul W S Heng
Journal:  Pharm Res       Date:  2008-06-26       Impact factor: 4.200

9.  Synthesis and Characterization of Nanocomposite Microparticles (nCmP) for the Treatment of Cystic Fibrosis-Related Infections.

Authors:  Zimeng Wang; Samantha A Meenach
Journal:  Pharm Res       Date:  2016-04-18       Impact factor: 4.200

10.  Composite particle formulations of colistin and meropenem with improved in-vitro bacterial killing and aerosolization for inhalation.

Authors:  Sharad Mangal; Heejun Park; Lingfei Zeng; Heidi H Yu; Yu-Wei Lin; Tony Velkov; John A Denman; Dmitry Zemlyanov; Jian Li; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2018-07-03       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.